Speakers

Justin Scheer is a senior pharmaceutical executive and computational biologist with extensive expertise in AI-driven drug discovery, bioinformatics, and structure-based design. He currently serves as Vice President, In Silico Discovery at Johnson & Johnson Innovative Medicine, where he leads a global molecular computational team delivering AI/ML, bioinformatics, cheminformatics, protein modeling, generative design, and structure-based drug design across all therapeutic discovery programs and platforms. 

Justin’s experience spans a wide range of modalities—including small molecules, peptides, antibodies, bispecifics, siRNA, gene therapy, cell therapy, and RNA therapeutics—across multiple therapeutic areas such as immunology, oncology, neurodegeneration, neuropsychiatry, retina, and cardiovascular/metabolic diseases. 

Previously, Justin held senior leadership roles at Boehringer Ingelheim overseeing biotherapeutics engineering and computational biochemistry, and at Genentech, where he contributed to antibody engineering, bispecific antibodies, Fc-fusion therapeutics, antibody-drug conjugates, and ocular therapeutics platform development.